Supply Chain Intelligence

Keros Therapeutics, Inc. Supply Chain

KROS supply chain intelligence for Keros Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

KROS ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

20Suppliers
30Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Keros Therapeutics, Inc. (KROS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

57Total relationships
4Distinct source URLs
7High confidence
0.734Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Keros Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
HANSOH-SHANGHAI-HEALTHTECH-CO-LTD HANSOH-SHANGHAI-HEALTHTECH-CO-LTD 90% We are dependent on our existing third-party collaborations with Takeda Pharmaceuticals U.S.A., Inc., or Takeda, and Hansoh (Shanghai) Healthtech Co., Ltd., or Hansoh, to commercial elritercept
TAKEDA-PHARMACEUTICALS-U-S-A-INC TAKEDA-PHARMACEUTICALS-U-S-A-INC 90% On December 3, 2024, the Company entered into a license agreement with Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), which became effective on January 16, 2025
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fa…
BMY Bristol-Myers Squibb Company 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: nued regulatory review, which may…
BMYMP Bristol-Myers Squibb Co 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
EWTX Edgewise Therapeutics, Inc. 72% Reciprocal relationship from EWTX graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
EWTX Edgewise Therapeutics, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
IBIO iBio, Inc. 72% Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. Ther…
MSLE MSLE 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
MSLE MSLE 72% Reciprocal relationship from MSLE graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: nued regulatory review, which may r…
REGN Regeneron Pharmaceuticals, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
RNAM RNAM 72% Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
RNAM RNAM 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
SRPT Sarepta Therapeutics, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
SRPT Sarepta Therapeutics, Inc. 72% Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
SRRK Scholar Rock Holding Corporation 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
SRRK Scholar Rock Holding Corporation 72% Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
TAK Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TAK graph: Reciprocal relationship from KROS graph: Reciprocal relationship from TAK graph: Reciprocal relationship from KROS graph: Reciprocal relationship from TAK grap…

Keros Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
HANSOH-SHANGHAI-HEALTHTECH-CO-LTD HANSOH-SHANGHAI-HEALTHTECH-CO-LTD 92% In connection with the Hansoh Agreement, Hansoh will purchase clinical trial supply of elritercept from the Company
MASSACHUSETTS-GENERAL-HOSPITAL MASSACHUSETTS-GENERAL-HOSPITAL 90% the Company has entered into an agreement with the Massachusetts General Hospital for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from KROS graph: Reciprocal relationship from BMY grap…
BMY Bristol-Myers Squibb Company 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we …
BMYMP Bristol-Myers Squibb Co 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
EWTX Edgewise Therapeutics, Inc. 72% Reciprocal relationship from EWTX graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
EWTX Edgewise Therapeutics, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
GOSS Gossamer Bio, Inc. 72% Reciprocal relationship from GOSS graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
GOSS Gossamer Bio, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
IBIO iBio, Inc. 72% Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO g…
MSLE MSLE 72% Reciprocal relationship from MSLE graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
MSLE MSLE 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
MYGN Myriad Genetics, Inc. 72% d parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that eve…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from KROS graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from KROS graph: d parties to advance our research o…
PTCT PTC Therapeutics, Inc. 72% Reciprocal relationship from PTCT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from PTCT g…
PTCT PTC Therapeutics, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
REGN Regeneron Pharmaceuticals, Inc. 72% Reciprocal relationship from REGN graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
REGN Regeneron Pharmaceuticals, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
RNAM RNAM 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
RNAM RNAM 72% Reciprocal relationship from RNAM graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
SLDB Solid Biosciences Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
SLDB Solid Biosciences Inc. 72% Reciprocal relationship from SLDB graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
SNYNF Sanofi 72% d parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that eve…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SNYN…
SRPT Sarepta Therapeutics, Inc. 72% Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SRPT g…
SRPT Sarepta Therapeutics, Inc. 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
SRRK Scholar Rock Holding Corporation 72% Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we f…
SRRK Scholar Rock Holding Corporation 72% nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems wi…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% tain a license to any third-party intellectual property related to the licensed products, and generic competition. The obligation to pay royalties under the MGH Agreement expires on a licensed produc…

Keros Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KROS-DEBT-10570 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
KROS-DEBT Debt stack $16.3M 90% Market cache reports total debt of $16.3M.

Keros Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Keros Therapeutics, Inc..

Keros Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
KROS-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 152 tracked holders.

Keros Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2

See the full supply chain map, all relationships, and real-time alerts for Keros Therapeutics, Inc..

Unlock full KROS data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
KROS
Unlock KROS Supply Chain Data
Verified relationships include:
HANSOH-SHANGHAI-HEALTHTECH-CO-LTDHANSOH-SHANGHAI-HEALTHTEC…Supplier90%
TAKEDA-PHARMACEUTICALS-U-S-A-INCTAKEDA-PHARMACEUTICALS-U-…Supplier90%
HANSOH-SHANGHAI-HEALTHTECH-CO-LTDHANSOH-SHANGHAI-HEALTHTEC…Customer92%
MASSACHUSETTS-GENERAL-HOSPITALMASSACHUSETTS-GENERAL-HOSPITALCustomer90%
+49 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →